STORM in the News
Thomas Meek talks to CEO Keith Blundy about STORM Therapeutics and the untapped RNA space
Read more
Keith Blundy, CEO of STORM Therapeutics, discusses the company’s founding and upcoming milestones.
Read more
Editor, Louise Fordham talks to CEO Keith Blundy about the latest developments at STORM Therapeutics and its plans for the year ahead
Read more
STORM Therapeutics Limited is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer.
Read more
PharmaVentures InSights interview CEO of STORM Therapeutics Keith Blundy
Read more